A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

Ronald L. Veselenak, Mark Shlapobersky, Richard Pyles, Qun Wei, Sean M. Sullivan, Nigel Bourne

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin®. Prophylactic immunization with Vaxfectin®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

Original languageEnglish (US)
Pages (from-to)7046-7051
Number of pages6
JournalVaccine
Volume30
Issue number49
DOIs
StatePublished - Nov 19 2012

Fingerprint

Herpes Genitalis
DNA Vaccines
Human Herpesvirus 2
Therapeutic Uses
recombinant vaccines
guinea pigs
genitalia
Immunization
plasmids
Guinea Pigs
Plasmids
therapeutics
immunization
Virus Shedding
Spinal Ganglia
Skin Diseases
viral shedding
Lipids
skin diseases
virus replication

Keywords

  • DNA vaccine
  • Herpes simplex virus type 2
  • Therapeutic vaccine
  • Vaxfectin

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. / Veselenak, Ronald L.; Shlapobersky, Mark; Pyles, Richard; Wei, Qun; Sullivan, Sean M.; Bourne, Nigel.

In: Vaccine, Vol. 30, No. 49, 19.11.2012, p. 7046-7051.

Research output: Contribution to journalArticle

Veselenak, Ronald L. ; Shlapobersky, Mark ; Pyles, Richard ; Wei, Qun ; Sullivan, Sean M. ; Bourne, Nigel. / A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. In: Vaccine. 2012 ; Vol. 30, No. 49. pp. 7046-7051.
@article{c056c99da12d4b80a149f28c83631300,
title = "A Vaxfectin{\circledR}-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes",
abstract = "Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin{\circledR}. Prophylactic immunization with Vaxfectin{\circledR}-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin{\circledR}-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.",
keywords = "DNA vaccine, Herpes simplex virus type 2, Therapeutic vaccine, Vaxfectin",
author = "Veselenak, {Ronald L.} and Mark Shlapobersky and Richard Pyles and Qun Wei and Sullivan, {Sean M.} and Nigel Bourne",
year = "2012",
month = "11",
day = "19",
doi = "10.1016/j.vaccine.2012.09.057",
language = "English (US)",
volume = "30",
pages = "7046--7051",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "49",

}

TY - JOUR

T1 - A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

AU - Veselenak, Ronald L.

AU - Shlapobersky, Mark

AU - Pyles, Richard

AU - Wei, Qun

AU - Sullivan, Sean M.

AU - Bourne, Nigel

PY - 2012/11/19

Y1 - 2012/11/19

N2 - Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin®. Prophylactic immunization with Vaxfectin®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

AB - Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin®. Prophylactic immunization with Vaxfectin®-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin®-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.

KW - DNA vaccine

KW - Herpes simplex virus type 2

KW - Therapeutic vaccine

KW - Vaxfectin

UR - http://www.scopus.com/inward/record.url?scp=84869078803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869078803&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.09.057

DO - 10.1016/j.vaccine.2012.09.057

M3 - Article

C2 - 23041125

AN - SCOPUS:84869078803

VL - 30

SP - 7046

EP - 7051

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 49

ER -